There are no approved drugs which act on fibrosis for any systemic disease
We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening chronic diseases, by developing innovative therapies underpinned by scientific excellence.
Our novel class of drugs has the potential to be an essential therapy in the treatment of serious inflammatory and fibrotic diseases, including systemic sclerosis, chronic kidney disease, focal segmental glomerulosclerosis, diabetic retinopathy and other diseases.
Our mission is to advance these novel therapeutics through clinical development to provide precision medicine treatments for these conditions.
Certa Therapeutics is a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases
Certa Therapeutics has designed a platform of candidate drugs and validated the role of a novel receptor which mediates signalling pathways associated with inflammation and fibrosis.
These targeted drugs have established proof of concept as potential treatments for multiple fibrotic diseases including serious and chronic conditions impacting the kidney, lung, eye, skin and heart. The morbidity and mortality impact of fibrotic diseases is substantial, ultimately causing 45% of all deaths globally.
Certa Therapeutics is seeking to combine these innovative therapeutics with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment. Significant breakthroughs are urgently needed in this field, addressing a market worth more than US$15B annually.
With a shared mission, Certa Therapeutics works closely with fellow Australian biotech company OccuRx.
Together, we’re developing a treatment platform for a spectrum of inflammatory and fibrotic diseases.
Certa Therapeutics and OccuRx are supported by common investment partners, led by Brandon BioCatalyst and Uniseed.